X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Fabrazyme (agalsidase beta) works by replacing a naturally occurring enzyme (alpha-galactosidase A) to help clear GL-3 build-up in cells, including those lining the blood vessels of the kidneys, heart and skin. It is the only FDA-approved therapy for Fabry disease.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabrazyme
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
Iran Expo
Not Confirmed
Contact Supplier
Details:
Through the agreement, mAbxience will be responsible for the manufacture of the active ingredient, developed by Biosidus as a biosimilar of Fabrazyme (agalsidase beta), which will be used for the treatment of Fabry disease.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biosidus S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2024
Details:
Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabagal
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: ISU ABXIS
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
The agreement includes the marketing alliance for JR-051 (agalsidase beta BS), a biosimilar of Fabrazyme, a therapeutic enzyme, being sold by JCR for the treatment of Fabry disease.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: JR-051
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sumitomo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2022
Details:
Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: Fabagal
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Petrovax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 26, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
